Immunogen : “I think it’s going to have a big year,” Cramer said of IMGN. He likes it as a speculative play on biotech.
Synchronoss Technologies : “It just had a very big move,” Cramer said, so investors should take profits.
Hi Tech Pharmacal : Cramer is bullish on HITK, he said, even at these price levels.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org